Author

M. C. Monti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:metabolomics· 1 Organism:mouse· 1 Assay:organoid / primary culture· 1

Frequent Co-Authors

A. Zampella· 2 shared B. Catalanotti· 2 shared C. Di Giorgio· 2 shared C. Massa· 2 shared E. Distrutti· 2 shared E. Morretta· 2 shared G. Urbani· 2 shared M. Biagioli· 2 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Zampella

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease

M. Biagioli, C. Di Giorgio, C. Massa, S. Marchiano', R. Bellini, M. Bordoni, G. Urbani, R. Roselli, G. Lachi, E. Morretta, F. Dal Piaz, B. Charlier, B. Fiorillo, B. Catalanotti, L. Cari, , S. Fiorucci

This study identifies 3-oxo-DCA as a microbial bile acid that acts as a GPBAR1 agonist and RORγt inverse agonist, reversing inflammation in IBD.

bioRxiv · Apr 8, 2024 · PreprintImmunology

Bile Acids Serve As Endogenous Antagonists Of The Leukemia Inhibitory Factor (LIF) Receptor in Oncogenesis

C. Di Giorgio, E. Morretta, A. Lupia, R. Bellini, C. Massa, G. Urbani, M. Bordoni, S. Marchiano, P. Rapacciuolo, C. Finamore, V. Sepe, M. C. Monti, F. Monarca, N. Natalizi, L. Graziosi, , S. Fiorucci

The paper shows bile acids, specifically GDCA, inhibit LIFR in gastric cancer, suggesting potential for bile acid-based therapies in LIF-driven oncogenesis.

bioRxiv · Sep 30, 2023Cancer Biology